Urokinase type plasminogen activator receptor expression in colorectal neoplasms

Gut

Volumn 43, Issue 6, 1998, Pages 798-805

  Suzuki, S ^a   Hayashi, Y ^a   Wang, Y ^c   Nakamura, T ^a   Morita, Y ^a   Kawasaki, K ^a   Ohta, K ^a   Aoyama, N ^a   Kim, S R ^b   Itoh, H ^a   Kuroda, Y ^a   Doe, W F ^d  

^a KOBE UNIVERSITY   (Japan)

^b KOBE ASAHI HOSPITAL   (Japan)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Australian National University   (Australia)

Author keywords

Adenoma carcinoma sequence; Colorectal adenoma; Colorectal cancer; Urokinase type plasminogen activator receptor

Indexed keywords

UROKINASE RECEPTOR;

ARTICLE; CANCER INVASION; CANCER STAGING; COLON ADENOMA; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; DYSPLASIA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; NORTHERN BLOTTING; PRIORITY JOURNAL; RECTUM ADENOMA;

EID: 7844244311     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.6.798     Document Type: Article

References (76)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
2. Liotta LA. Tumor invasion and metastasis role of the extracellular matrix. Cancer Res 1986;46:1-7.
3. Tryggvason K, Höyhtyä M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochem Biophys Acta 1987;907:191-217.
4. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Ann Rev Biochem 1986;55:1037-57.
5. Laiho M, Keski-oja J. Growth factors in the regulation of pericellular proteolysis. Cancer Res 1989;49:2533-53.
6. Dano K, Andreasen PA, Grøndahl-Hansen J, et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-26.
7. Blasi F, Vassalli J-D, Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987;104:801-4.
8. Keski-oja J, Kori K, Lohi J, et al. Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin Thromb Hemost 1991;17:231-9.
9. Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzyme: regulation of activity by organ factors. Semin Cancer Biol 1991;2:115-27.
10. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. J Biol Chem 1991;266:12752-8.
11. Hollas W, Blasi F, Boyd D. Role of urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991;51:3690-5.
12. Veale D, Needham G, Harris AL. Urokinase receptors in lung cancer and normal lung. Anticancer Res 1990;10:417-22.
13. Schlechte W, Brattain M, Boyd D. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. Cancer Commun 1990;2:173-9.
14. Hoosein NM, Boyd D, Hollas WJ, et al. Involvement of urokinase and its receptor in invasiveness of human prostatic carcinoma cell lines. Cancer Commun 1991;3:255-64.
15. Olsen O, Pöllänen J, Høyer-Hansen G, et al. Internalization of the urokinase-plasminogen activator inhibitor type 1 complex is mediated by the urokinase receptor. J Biol Chem 1992;267:9129-33.
16. Baker MS, Bleakley P, Woodrow GC, et al. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 1990;50:4676-84.
17. Nielsen BS, Sehested M, Timshel S, et al. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74:168-77.
18. Bianchi E, Cohen RL, Thor AT, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994;54:861-6.
19. Pyke C, Græm N, Ralfkiær E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-5.
20. Casslen B, Gusstausson B, Astedt B. Cell membrane receptor for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur J Cancer 1991;27:1445-8.
21. Vries TJ, Quax PHA, Denijn M, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-81.
22. Wagner SN, Atkinson MJ, Thanner S, et al. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol 1995;147:183-92.
23. Zheng MH, Fan Y, Panicker A, et al. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. Am J Pathol 1995;147:1554-66.
24. Reilly D, Christensen L, Duch M, et al. Type-1 plasminogen activator inhibitor in human breast carcinoma. Int J Cancer 1992;50:208-14.
25. Foekens JA, Schmidtt M, van Putten WLJ, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-5.
26. Hasui Y, Marutsuka K, Suzumiya J, et al. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992;50:871-3.
27. Grøndahl-Hansen J, Peters HA, van Putten WLJ, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-87.
28. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53: 2513-21.
29. Ito H, Yonemura Y, Fujita H, et al. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch 1996;427:487-96.
30. Sier CFM, Vloedgraven HJM, Ganesh S, et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994; 107:1449-56.
31. Ganesh S, Sier CFM, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-71.
32. Ganesh S, Sier CFM, Heerding MM, et al. Urokinase receptor and colorectal cancer survival. Lancet 1994;344: 401-2.
33. Sim Pheng-Siew, Stephens RW, Fayle DRH, et al. Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme. Int J Cancer 1988;42:482-8.
34. Gelister JSK, Lewin MR, Savage F, et al. Plasminogen activators in experimental colorectal neoplasia: a role in adenoma-carcinoma sequence? Gut 1987;28:816-21.
35. Suzumiya J, Hasui Y, Kohga S, et al. Comparative study of plasminogen activator antigen in colonie carcinomas and adenomas. Int J Cancer 1988;42:627-32.
36. de Bruin PAF, Griffioen G, Verspaget HW, et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 1988;48:4520-4.
37. de Bruin PAF, Griffioen G, Verspaget HW, et al. Plasminogen activators and tumor development in the human colon: activity level in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987;47:4654-7.
38. Pyke C, Kristensen P, Ralfkiær E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-67.
39. Sier CFM, Fellbaum C, Verspaget HW, et al. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology 1991;19:231-7.
40. Pyke C, Kristensen P, Ralfkiær E, et al. The plasminogen activator system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991;51:4067-71.
41. Sier CFM, Quax PHA, Vloedgraven HJM, et al. Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastasis. Invasion Metastasis 1993;13: 277-88.
42. Sier CFM, Verspaget HW, Griffioen G, et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology 1991;101:1522-8.
43. Pyke C, Ralfkiær E, Rønne E, et al. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994;24:131-8.
44. Morita Y, Hayashi Y, Wang Y, et al. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology 1997;25:856-61.
45. Cohen RL, Xi X-P, Crowley CW, et al. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 1991; 78:479-87.
46. Peiter LS, Kruithof EKO, Cajot J-F, et al. The role of the urokinase receptor in extracellular matrix degradation by HT 29 human colon carcinoma cells. Int J Cancer 1993;53: 444-50.
47. Wang H, Skibber J, Juarez J, et al. Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 1994;58:650-7.
48. Crowley CW, Cohen RL, Lucas BK, et al. Prevention of metastasis by inhibition of urokinase receptor. Proc Natl Acad Sci USA 1993;90:5021-5.
49. Kook YH, Adamski J, Zelent A, et al. The effect of antisense inhibition of receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91.
50. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-33.
51. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
52. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994;54:3066-71.
53. Nip J, Rabbani SA, Shibata HR, et al. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 1994;95:2096-103.
54. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
55. Xue W, Mizutani I, Todd III RF, et al. Urokinase-type plasminogen activator receptors associate with b1 and b3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997;57:1682-9.
56. Waltz DA, Natkin LR, Fujita RM, et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100: 58-67.
57. Muto T, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70.
58. Delbaldo C, Cunningham M, Vassalli JD, et al. Plasmin-catalyzed proteolysis in colorectal neoplasia. Cancer Res 1995;55:4688-95.
59. Sordat I, Chaubert P, Protiva P, et al. In situ stromal expression of the urokinase plasmin system correlates with epithelial dysplasia in colorectal adenomas. Am J Pathol 1997;150:283-95.
60. Jass JR, Sobin LH. Histological typing of intestional tumours. In: WHO international histological classification of tumours. Berlin: Springer-Verlag, 1989.
61. Dukes EC. The classification of cancer of the rectum. J Pathol Bacterioll 1932;35:323-32.
62. Springer JE, Robbins E, Gwag BJ, et al. Non-radiographic detection of nerve growth factor receptor (NGFR) mRNA in rat brain using in situ hybridization histochemistry. J Histochem Cytochem 1991;39:231-4.
63. Kohri K, Nomura S, Kitamura Y, et al. Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 1993;268:15180-4.
64. eRBB2 expression and the gene amplification. Cancer Res 1990;50:8002-9.
65. Andreasen PA, Kjøller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
66. Li C, Liu J-N, Gurewich V. Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. J Biol Chem 1995;270:30282-5.
67. Resnati M, Guttinger M, Valcamonica S, et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15: 1572-82.
68. Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
69. Almus-Jacobs F, Varki N, Sawdey MS, et al. Endotoxin stimulates expression of the murine urokinase receptor gene in vitro. Am J Pathol 1995;147:688-98.
70. Dang J, Wang Y, Doe WF. Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription level in colon cancer cells. FEBS Lett 1995;359:147-50.
71. Antalis TM, Reeder JA. Butyrate regulates gene expression of the plasminogen activating system in colon cancer cells. Int J Cancer 1995;62:619-26.
72. Lund LR, Ellis V, Rønne E, et al. Transcriptional and post transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem J 1995;310:345-52.
73. Ploug M, Rønne E, Behrendt N, et al. Cellular receptor for urokinase plasminogen activator carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidyl-mositol. J Biol Chem 1991;266:1926-33.
74. Behrendt N, Rønne E, Danø K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe-Seyler 1995;376:269-79.
75. Behrent N, Ronne E, Ploug M, et al. The human receptor for urokinase plasminogen activator: NH2-terminal amino acid sequence and glycosylation vaariants. J Biol Chem 1990;265:6453-60.
76. Luther T, Magdolen V, Albrecht S, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997;150:1231-44.